ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 42829916

CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells.

Xu Z and 6 others. Adv Sci (Weinh), 2026.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells. Papers, record 42829916. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42829916

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells.
Journal
Adv Sci (Weinh)
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-10-06

Source PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Xu ZZhuoshuohttps://orcid.org/0000-0002-8312-2163
2Zhang XXinyu
3Dong FFang
4Shen NNenghao
5Zhou JJunhttps://orcid.org/0000-0002-9449-0471
6Xi ZZihan
7Wu ZZhenghaohttps://orcid.org/0000-0001-8468-1234

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82673430Natural Science Foundation of ChinaPubMed
82303179Natural Science Foundation of ChinaPubMed
82404027Natural Science Foundation of ChinaPubMed
82503923Natural Science Foundation of ChinaPubMed
2024AFB626Natural Science Foundation of Hubei ProvincePubMed
2025AFD800Natural Science Foundation of Hubei ProvincePubMed
2026AFB530Natural Science Foundation of Hubei ProvincePubMed
2023-36Hubei Province Postdoctoral Innovation Practice ProgramPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References82

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133,546,704The cancer metabolic reprogramming and immune response.Mol Cancer2021https://conductscience.org/library/papers/33546704PubMed
231,570,880Tumour-intrinsic resistance to immune checkpoint blockade.Nat Rev Immunol2020https://conductscience.org/library/papers/31570880PubMed
341,291,745RHOA lactylation at oncogenic hotspots promotes oncogenic activity and protein stabilization.Mol Cancer2025https://conductscience.org/library/papers/41291745PubMed
435,101,946TSH-TSHR axis promotes tumor immune evasion.J Immunother Cancer2022https://conductscience.org/library/papers/35101946PubMed
540,073,846Lactate: A key regulator of the immune response.Immunity2025https://conductscience.org/library/papers/40073846PubMed
639,156,900The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.Front Immunol2024https://conductscience.org/library/papers/39156900PubMed
738,273,398Exploring non-invasive precision treatment in non-small cell lung cancer patients through deep learning radiomics across imaging features and molecular phenotypes.Biomark Res2024https://conductscience.org/library/papers/38273398PubMed
840,073,861The role of protein lactylation: A kaleidoscopic post-translational modification in cancer.Mol Cell2025https://conductscience.org/library/papers/40073861PubMed
925,858,804Immune checkpoint blockade: a common denominator approach to cancer therapy.Cancer Cell2015https://conductscience.org/library/papers/25858804PubMed
1038,181,797Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.Cancer Cell2024https://conductscience.org/library/papers/38181797PubMed

1 to 10 of 82

See all 82 references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first.

PMIDTitleJournalYearIn Papers
42,829,916CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42829916

Source PubMed

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42829916

GET https://conductscience.org/api/papers/v1/42829916/references?page=2

API referenceFor AI assistants